Leishmania spp. proteome data sets: A comprehensive resource for vaccine development to target visceral leishmaniasis

Frontiers in Immunology

Volumn 5, Issue JUN, 2014, Pages

  Aebischer, Toni ^a  

^a ROBERT KOCH INSTITUTE   (Germany)

Author keywords

Kinetoplastida; Major histocompatibility complex antigens; Proteome; T cell antigen receptor; Vaccine

Indexed keywords

EID: 84905656755     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00260     Document Type: Article

References (81)

1. Singh B, Sundar S. Leishmaniasis: vaccine candidates and perspectives. Vaccine (2012) 30(26):3834-42. doi: 10.1016/j.vaccine.2012.03.068
2. Kedzierski L. Leishmaniasis vaccine: where are we today? J Glob Infect Dis (2010) 2(2):177-85. doi:10.4103/0974-777X.62881
3. Mathers CD, Ezzati M, Lopez AD. Measuring the burden of neglected tropical diseases: the global burden of disease framework. PLoS Negl Trop Dis (2007) 1(2):e114. doi:10.1371/journal.pntd.0000114
4. Olliaro PL, Guerin PJ, Gerstl S, Haaskjold AA, Rottingen JA, Sundar S. Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004. Lancet Infect Dis (2005) 5(12):763-74. doi:10.1016/S1473-3099(05)70296-6
5. Lee BY, Bacon KM, Shah M, Kitchen SB, Connor DL, Slayton RB. The economic value of a visceral leishmaniasis vaccine in Bihar state, India. Am J Trop Med Hyg (2012) 86(3):417-25. doi:10.4269/ajtmh.2012.10-0415
6. Fernandes AP, Coelho EA, Machado-Coelho GL, Grimaldi GJ, Gazzinelli RT. Making an anti-amastigote vaccine for visceral leishmaniasis: rational, update and perspectives. Curr Opin Microbiol (2012) 15(4):476-85. doi:10.1016/j.mib.2012.05.002
7. Belkaid Y, Von SE, Mendez S, Lira R, Caler E, Bertholet S, et al. CD8+ T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major. J Immunol (2002) 168(8):3992-4000. doi:10.4049/jimmunol.168.8.3992
8. Gautam S, Kumar R, Singh N, Singh AK, Rai M, Sacks D, et al. CD8 T cell exhaustion in human visceral leishmaniasis. J Infect Dis (2014) 209(2):290-9. doi:10.1093/infdis/jit401
9. + (Foxp3) regulatory T cells in human visceral leishmaniasis. J Exp Med (2007) 204(4):805-17. doi:10.1084/jem.20061141
10. Stauch A, Sarkar RR, Picado A, Ostyn B, Sundar S, Rijal S, et al. Visceral leishmaniasis in the Indian subcontinent: modelling epidemiology and control. PLoS Negl Trop Dis (2011) 5(11):e1405. doi:10.1371/journal.pntd.0001405
11. Ostyn B, Gidwani K, Khanal B, Picado A, Chappuis F, Singh SP, et al. Incidence of symptomatic and asymptomatic Leishmania donovani infections in high-endemic foci in India and Nepal: a prospective study. PLoS Negl Trop Dis (2011) 5(10):e1284. doi:10.1371/journal.pntd.0001284
12. Nadim A, Javadian E, Tahvildar-Bidruni G, Ghorbani M. Effectiveness of leishmanization in the control of cutaneous leishmaniasis. Bull Soc Pathol Exot Filiales (1983) 76(4):377-83.
13. Hosseini SM, Hatam GR, Ardehali S. Characterization of Leishmania isolated from unhealed lesions caused by leishmanization. East Mediterr Health J (2005) 11(1-2):240-3.
14. Khamesipour A, Dowlati Y, Asilian A, Hashemi-Fesharki R, Javadi A, Noazin S, et al. Leishmanization: use of an old method for evaluation of candidate vaccines against leishmaniasis. Vaccine (2005) 23(28):3642-8. doi:10.1016/j.vaccine.2005.02.015
15. Dey R, Dagur PK, Selvapandiyan A, McCoy JP, Salotra P, Duncan R, et al. Live attenuated Leishmania donovani p27 gene knockout parasites are nonpathogenic and elicit long-term protective immunity in BALB/c mice. J Immunol (2013) 190(5):2138-49. doi:10.4049/jimmunol.1202801
16. Spath GF, Lye LF, Segawa H, Turco SJ, Beverley SM. Identification of a compensatory mutant (lpg2-REV) of Leishmania major able to survive as amastigotes within macrophages without LPG2-dependent glycoconjugates and its significance to virulence and immunization strategies. Infect Immun (2004) 72(6):3622-7. doi:10.1128/IAI.72.6.3622-3627.2004
17. Titus RG, Gueiros-Filho FJ, de Freitas LA, Beverley SM. Development of a safe live Leishmania vaccine line by gene replacement. Proc Natl Acad Sci U S A (1995) 92(22):10267-71. doi:10.1073/pnas.92.22.10267
18. Fiuza JA, Santiago Hda C, Selvapandiyan A, Gannavaram S, Ricci ND, Bueno LL, et al. Induction of immunogenicity by live attenuated Leishmania donovani centrin deleted parasites in dogs. Vaccine (2013) 31(14):1785-92. doi:10.1016/j.vaccine.2013.01.048
19. Saljoughian N, Taheri T, Rafati S. Live vaccination tactics: possible approaches for controlling visceral leishmaniasis. Front Immunol (2014) 5:134. doi:10.3389/fimmu.2014.00134
20. Coler RN, Reed SG. Second-generation vaccines against leishmaniasis. Trends Parasitol (2005) 21(5):244-9. doi:10.1016/j.pt.2005.03.006
21. Darrah PA, Hegde ST, Patel DT, Lindsay RW, Chen L, Roederer M, et al. IL-10 production differentially influences the magnitude, quality, and protective capacity of Th1 responses depending on the vaccine platform. J Exp Med (2010) 207(7):1421-33. doi:10.1084/jem.20092532
22. Maroof A, Brown N, Smith B, Hodgkinson MR, Maxwell A, Losch FO, et al. Therapeutic vaccination with recombinant adenovirus reduces splenic parasite burden in experimental visceral leishmaniasis. J Infect Dis (2012) 205(5):853-63. doi:10.1093/infdis/jir842
23. Yang DM, Fairweather N, Button LL, McMaster WR, Kahl LP, Liew FY. Oral Salmonella typhimurium (AroA-) vaccine expressing a major leishmanial surface protein (gp63) preferentially induces T helper 1 cells and protective immunity against leishmaniasis. J Immunol (1990) 145(7):2281-5.
24. Schroeder J, Aebischer T. Vaccines for leishmaniasis: from proteome to vaccine candidates. Hum Vaccin (2011) 7: doi:10.4161/hv.7.0.14556
25. Singh OP, Gidwani K, Kumar R, Nylen S, Jones SL, Boelaert M, et al. Reassessment of immune correlates in human visceral leishmaniasis as defined by cytokine release in whole blood. Clin Vaccine Immunol (2012) 19(6):961-6. doi:10.1128/CVI.00143-12
26. Rappuoli R. Reverse vaccinology. Curr Opin Microbiol (2000) 3(5):445-50. doi:10.1016/S1369-5274(00)00119-3
27. Pizza M, Scarlato V, Masignani V, Giuliani MM, Arico B, Comanducci M, et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science (2000) 287(5459):1816-20. doi:10.1126/science.287.5459.1816
28. John L, John GJ, Kholia T. A reverse vaccinology approach for the identification of potential vaccine candidates from Leishmania spp. Appl Biochem Biotechnol (2012) 167(5):1340-50. doi:10.1007/s12010-012-9649-0
29. Resende DM, Rezende AM, Oliveira NJ, Batista IC, Correa-Oliveira R, Reis AB, et al. An assessment on epitope prediction methods for protozoa genomes. BMC Bioinformatics (2012) 13:309. doi:10.1186/1471-2105-13-309
30. Herrera-Najera C, Pina-Aguilar R, Xacur-Garcia F, Ramirez-Sierra MJ, Dumonteil E. Mining the Leishmania genome for novel antigens and vaccine candidates. Proteomics (2009) 9(5):1293-301. doi:10.1002/pmic.200800533
31. Ouakad M, Bahi-Jaber N, Chenik M, Dellagi K, Louzir H. Selection of endogenous reference genes for gene expression analysis in Leishmania major developmental stages. Parasitol Res (2007) 101(2):473-7. doi:10.1007/s00436-007-0491-1
32. Ben-Othman R, Guizani-Tabbane L, Dellagi K. Leishmania initially activates but subsequently down-regulates intracellular mitogen-activated protein kinases and nuclear factor-kappaB signaling in macrophages. Mol Immunol (2008) 45(11):3222-9. doi:10.1016/j.molimm.2008.02.019
33. Antoine JC, Prina E, Jouanne C, Bongrand P. Parasitophorous vacuoles of Leishmania amazonensis-infected macrophages maintain an acidic pH. Infect Immun (1990) 58(3):779-87.
34. Courret N, Frehel C, Gouhier N, Pouchelet M, Prina E, Roux P, et al. Biogenesis of Leishmania-harbouring parasitophorous vacuoles following phagocytosis of the metacyclic promastigote or amastigote stages of the parasites. J Cell Sci (2002) 115:2303-16.
35. Burchmore RJ, Barrett MP. Life in vacuoles - nutrient acquisition by Leishmania amastigotes. Int J Parasitol (2001) 31(12):1311-20. doi:10.1016/S0020-7519(01)00259-4
36. Collins HL, Schaible UE, Ernst JD, Russell DG. Transfer of phagocytosed particles to the parasitophorous vacuole of Leishmania mexicana is a transient phenomenon preceding the acquisition of annexin I by the phagosome. J Cell Sci (1997) 110(Pt 2):191-200.
37. Muraille E, Cazareth J, Gounon P, Hoebeke J, Lippuner C, Soares H, et al. Visualization of peptide/MHC complexes at the surface and in the intracellular compartments of cells infected in vivo by Leishmania major. PLoS Pathog (2010) 6(10):e1001154. doi:10.1371/journal.ppat.1001154
38. Lambertz U, Silverman JM, Nandan D, McMaster WR, Clos J, Foster LJ, et al. Secreted virulence factors and immune evasion in visceral leishmaniasis. J Leukoc Biol (2012) 91(6):887-99. doi:10.1189/jlb.0611326
39. Silverman JM, Clos J, Horakova E, Wang AY, Wiesgigl M, Kelly I, et al. Leishmania exosomes modulate innate and adaptive immune responses through effects on monocytes and dendritic cells. J Immunol (2010) 185(9):5011-22. doi:10.4049/jimmunol.1000541
40. Wolfram M, Fuchs M, Wiese M, Stierhof YD, Overath P. Antigen presentation by Leishmania mexicana-infected macrophages: activation of helper T cells by a model parasite antigen secreted into the parasitophorous vacuole or expressed on the amastigote surface. Eur J Immunol (1996) 26(12):3153-62. doi:10.1002/eji.1830261248
41. Bertholet S, Goldszmid R, Morrot A, Debrabant A, Afrin F, Collazo-Custodio C, et al. Leishmania antigens are presented to CD8+ T cells by a transporter associated with antigen processing-independent pathway in vitro and in vivo. J Immunol (2006) 177(6):3525-33. doi:10.4049/jimmunol.177.6.3525
42. Prickett S, Gray PM, Colpitts SL, Scott P, Kaye PM, Smith DF. In vivo recognition of ovalbumin expressed by transgenic Leishmania is determined by its subcellular localization. J Immunol (2006) 176(8):4826-33. doi:10.4049/jimmunol.176.8.4826
43. Bertholet S, Debrabant A, Afrin F, Caler E, Mendez S, Tabbara KS, et al. Antigen requirements for efficient priming of CD8+ T cells by Leishmania major-infected dendritic cells. Infect Immun (2005) 73(10):6620-8. doi:10.1128/IAI.73.10.6620-6628.2005
44. Misslitz AC, Bonhagen K, Harbecke D, Lippuner C, Kamradt T, Aebischer T. Two waves of antigen-containing dendritic cells in vivo in experimental Leishmania major infection. Eur J Immunol (2004) 34(3):715-25. doi:10.1002/eji.200324391
45. Schmid M, Wege AK, Ritter U. Characteristics of "Tip-DCs and MDSCs" and their potential role in leishmaniasis. Front Microbiol (2012) 3:74. doi:10.3389/fmicb.2012.00074
46. Filipe-Santos O, Pescher P, Breart B, Lippuner C, Aebischer T, Glaichenhaus N, et al. A dynamic map of antigen recognition by CD4 T cells at the site of Leishmania major infection. Cell Host Microbe (2009) 6(1):23-33. doi:10.1016/j.chom.2009.04.014
47. Muller AJ, Filipe-Santos O, Eberl G, Aebischer T, Spath GF, Bousso P. CD4+ T cells rely on a cytokine gradient to control intracellular pathogens beyond sites of antigen presentation. Immunity (2012) 37(1):147-57. doi:10.1016/j.immuni.2012.05.015
48. Wolfram M, Ilg T, Mottram JC, Overath P. Antigen presentation by Leishmania mexicana-infected macrophages: activation of helper T cells specific for amastigote cysteine proteinases requires intracellular killing of the parasites. Eur J Immunol (1995) 25(4):1094-100. doi:10.1002/eji.1830250435
49. Courret N, Prina E, Mougneau E, Saraiva EM, Sacks DL, Glaichenhaus N, et al. Presentation of the Leishmania antigen LACK by infected macrophages is dependent upon the virulence of the phagocytosed parasites. Eur J Immunol (1999) 29(3):762-73. doi:10.1002/(SICI)1521-4141(199903)29:03<762::AID-IMMU762>3.0.CO;2-4
50. Inaba K, Turley S, Iyoda T, Yamaide F, Shimoyama S, Reis e Sousa C, et al. The formation of immunogenic major histocompatibility complex class II-peptide ligands in lysosomal compartments of dendritic cells is regulated by inflammatory stimuli. J Exp Med (2000) 191(6):927-36. doi:10.1084/jem.191.6.927
51. Santambrogio L, Sato AK, Fischer FR, Dorf ME, Stern LJ. Abundant empty class II MHC molecules on the surface of immature dendritic cells. Proc Natl Acad Sci U S A (1999) 96(26):15050-5. doi:10.1073/pnas.96.26.15050
52. Pierre P, Turley SJ, Gatti E, Hull M, Meltzer J, Mirza A, et al. Developmental regulation of MHC class II transport in mouse dendritic cells. Nature (1997) 388(6644):787-92. doi:10.1038/42039
53. Yewdell JW, Reits E, Neefjes J. Making sense of mass destruction: quantitating MHC class I antigen presentation. Nat Rev Immunol (2003) 3(12):952-61. doi:10.1038/nri1250
54. Delamarre L, Holcombe H, Mellman I. Presentation of exogenous antigens on major histocompatibility complex (MHC) class I and MHC class II molecules is differentially regulated during dendritic cell maturation. J Exp Med (2003) 198(1):111-22. doi:10.1084/jem.20021542
55. Su RC, Miller RG. Stability of surface H-2K(b), H-2D(b), and peptide-receptive H-2K(b) on splenocytes. J Immunol (2001) 167(9):4869-77. doi:10.4049/jimmunol.167.9.4869
56. Sykulev Y, Joo M, Vturina I, Tsomides TJ, Eisen HN. Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T cell response. Immunity (1996) 4(6):565-71. doi:10.1016/S1074-7613(00)80483-5
57. Kimachi K, Croft M, Grey HM. The minimal number of antigen-major histocompatibility complex class II complexes required for activation of naive and primed T cells. Eur J Immunol (1997) 27(12):3310-7. doi:10.1002/eji.1830271230
58. Manz BN, Jackson BL, Petit RS, Dustin ML, Groves J. T-cell triggering thresholds are modulated by the number of antigen within individual T-cell receptor clusters. Proc Natl Acad Sci U S A (2011) 108(22):9089-94. doi:10.1073/pnas.1018771108
59. Overath P, Aebischer T. Antigen presentation by macrophages harboring intravesicular pathogens. Parasitol Today (1999) 15(8):325-32. doi:10.1016/S0169-4758(99)01473-8
60. Ivens AC, Peacock CS, Worthey EA, Murphy L, Aggarwal G, Berriman M, et al. The genome of the kinetoplastid parasite, Leishmania major. Science (2005) 309(5733):436-42. doi:10.1126/science.1112680
61. Newell EW, Ely LK, Kruse AC, Reay PA, Rodriguez SN, Lin AE, et al. Structural basis of specificity and cross-reactivity in T cell receptors specific for cytochrome c-I-E(k). J Immunol (2011) 186(10):5823-32. doi:10.4049/jimmunol.1100197
62. Sharav T, Wiesmuller KH, Walden P. Mimotope vaccines for cancer immunotherapy. Vaccine (2007) 25(16):3032-7. doi:10.1016/j.vaccine.2007.01.033
63. Hastings KT. GILT: shaping the MHC class II-restricted peptidome and CD4 T cell-mediated immunity. Front Immunol (2013) 4:429. doi:10.3389/fimmu.2013.00429
64. Olekhnovitch R, Ryffel B, Muller AJ, Bousso P. Collective nitric oxide production provides tissue-wide immunity during Leishmania infection. J Clin Invest (2014) 124(4):1711-22. doi:10.1172/JCI72058
65. Aebischer T, Harbecke D, Ilg T. Proteophosphoglycan, a major secreted product of intracellular Leishmania mexicana amastigotes, is a poor B-cell antigen and does not elicit a specific conventional CD4+ T-cell response. Infect Immun (1999) 67(10):5379-85.
66. Paape D, Barrios-Llerena ME, Le BT, Mackay L, Aebischer T. Gel free analysis of the proteome of intracellular Leishmania mexicana. Mol Biochem Parasitol (2010) 169(2):108-14. doi:10.1016/j.molbiopara.2009.10.009
67. Nirujogi RS, Pawar H, Renuse S, Kumar P, Chavan S, Sathe G, et al. Moving from unsequenced to sequenced genome: reanalysis of the proteome of Leishmania donovani. J Proteomics (2014) 97:48-61. doi:10.1016/j.jprot.2013.04.021
68. Pescher P, Blisnick T, Bastin P, Spath GF. Quantitative proteome profiling informs on phenotypic traits that adapt Leishmania donovani for axenic and intracellular proliferation. Cell Microbiol (2011) 13(7):978-91. doi:10.1111/j.1462-5822.2011.01593.x
69. Paape D, Aebischer T. Contribution of proteomics of Leishmania spp. to the understanding of differentiation, drug resistance mechanisms, vaccine and drug development. J Proteomics (2011) 74(9):1614-24. doi:10.1016/j.jprot.2011.05.005
70. Sardar AH, Kumar S, Kumar A, Purkait B, Das S, Sen A, et al. Proteome changes associated with Leishmania donovani promastigote adaptation to oxidative and nitrosative stresses. J Proteomics (2013) 81:185-99. doi:10.1016/j.jprot.2013.01.011
71. Biyani N, Madhubala R. Quantitative proteomic profiling of the promastigotes and the intracellular amastigotes of Leishmania donovani isolates identifies novel proteins having a role in Leishmania differentiation and intracellular survival. Biochim Biophys Acta (2012) 1824(12):1342-50. doi:10.1016/j.bbapap.2012.07.010
72. Singh AK, Roberts S, Ullman B, Madhubala R. A quantitative proteomic screen to identify potential drug resistance mechanism in alpha-difluoromethylornithine (DFMO) resistant Leishmania donovani. J Proteomics (2014) 102:44-59. doi:10.1016/j.jprot.2014.02.030
73. Santarem N, Racine G, Silvestre R, Cordeiro-da-Silva A, Ouellette M. Exoproteome dynamics in Leishmania infantum. J Proteomics (2013) 84:106-18. doi:10.1016/j.jprot.2013.03.012
74. Ishihama Y, Oda Y, Tabata T, Sato T, Nagasu T, Rappsilber J, et al. Exponentially modified protein abundance index (emPAI) for estimation of absolute protein amount in proteomics by the number of sequenced peptides per protein. Mol Cell Proteomics (2005) 4(9):1265-72. doi:10.1074/mcp.M500061-MCP200
75. Lazarski CA, Chaves FA, Jenks SA, Wu S, Richards KA, Weaver JM, et al. The kinetic stability of MHC class II:peptide complexes is a key parameter that dictates immunodominance. Immunity (2005) 23(1):29-40. doi:10.1016/j.immuni.2005.05.009
76. Sijts AJ, Pamer EG. Enhanced intracellular dissociation of major histocompatibility complex class I-associated peptides: a mechanism for optimizing the spectrum of cell surface-presented cytotoxic T lymphocyte epitopes. J Exp Med (1997) 185(8):1403-11. doi:10.1084/jem.185.8.1403
77. Carter KC, Henriquez FL, Campbell SA, Roberts CW, Nok A, Mullen AB, et al. DNA vaccination against the parasite enzyme gamma-glutamylcysteine synthetase confers protection against Leishmania donovani infection. Vaccine (2007) 25(22):4502-9. doi:10.1016/j.vaccine.2007.03.014
78. Henriquez FL, Campbell SA, Roberts CW, Mullen AB, Burchmore R, Carter KC. Vaccination with recombinant Leishmania donovani gamma-glutamylcysteine synthetase fusion protein protects against L. donovani infection. J Parasitol (2010) 96(5):929-36. doi:10.1645/GE-2360.1
79. Campbell SA, Alawa J, Doro B, Henriquez FL, Roberts CW, Nok A, et al. Comparative assessment of a DNA and protein Leishmania donovani gamma glutamyl cysteine synthetase vaccine to cross-protect against murine cutaneous leishmaniasis caused by L. major or L. mexicana infection. Vaccine (2012) 30(7):1357-63. doi:10.1016/j.vaccine.2011.12.067
80. Julia V, McSorley SS, Malherbe L, Breittmayer JP, Girard-Pipau F, Beck A, et al. Priming by microbial antigens from the intestinal flora determines the ability of CD4+ T cells to rapidly secrete IL-4 in BALB/c mice infected with Leishmania major. J Immunol (2000) 165(10):5637-45. doi:10.4049/jimmunol.165.10.5637
81. Schroeder J, Brown N, Kaye P, Aebischer T. Single dose novel Salmonella vaccine enhances resistance against visceralizing L. major and L. donovani infection in susceptible BALB/c mice. PLoS Negl Trop Dis (2011) 5(12):e1406. doi:10.1371/journal.pntd.0001406